GlassScriptPhysician profile
Martha J Solomon
NPI 1861411787
$693.23
in general payments reported to CMS, 2019-2025
15 companies · $86.60 in 2025
The $86.60 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.43 · 2020: $40.12 · 2021: $45.35 · 2022: $184 · 2023: $160 · 2024: $116 · 2025: $86.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $170.49 | 2022-2025 | Evos, Panta 2, Healicoil |
| Bioventus LLC | $69.51 | 2022-2024 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Horizon Therapeutics Plc | $66.89 | 2022 | |
| Organogenesis INC. | $45.91 | 2022 | |
| Djo, LLC | $45.52 | 2024-2025 | Cmf |
| Depuy Synthes Sales INC. | $45.33 | 2021-2023 | Orthovisc |
| Osiris Therapeutics INC. | $41.16 | 2019 | |
| Dynasplint Systems INC. | $34.81 | 2023 | Dynasplint |
| Treace Medical Concepts, INC. | $34.66 | 2023 | |
| Averitas Pharma INC. | $32.23 | 2025 | Qutenza |
| Kci USA, INC. | $27.30 | 2021 | |
| Akcea Therapeutics, INC. | $25.91 | 2020 | |
| Zyla Life Sciences, INC. | $20.27 | 2019 | |
| Biotronik Nro, INC. | $19.03 | 2024 | Prospera |
| Zimmer Biomet Holdings, INC. | $14.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.